Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Kidney and Urinary TractDRG 700-other-kidney-and-urinary-tract-diagnoses-without-cc-mcc
    Ask Trek AI about this page

    Other Kidney and Urinary Tract Diagnoses without CC/MCC: Inpatient Reimbursement Overview

    DRG 700 encompasses inpatient stays for other kidney and urinary tract diagnoses without Complication or Comorbidity or Major Complication or Comorbidity, focusing on lower-severity conditions treated with medical management or minor procedures. Proper clinical documentation and coding determine assignment to this Diagnosis-Related Group, which influences Medicare inpatient reimbursement levels.

    Customize your policy alerts

    Sign up for drg 700 policy alerts

    Get alerted when payer policies referencing 700 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 700 Overview

    DRG 700 covers inpatient episodes for a range of kidney and urinary tract diagnoses that do not present with a Complication or Comorbidity or a Major Complication or Comorbidity. Typical cases include uncomplicated infections, benign urinary conditions, and nonspecific renal disorders managed primarily with medical care or simple procedures. This Diagnosis-Related Group matters for Medicare payment because it represents lower-severity admissions with correspondingly lower resource use and payment relative to higher-severity groupings. Accurate coding of diagnoses and procedures determines assignment to this Diagnosis-Related Group and thus affects inpatient reimbursement.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Prospective randomized or pragmatic comparative effectiveness studies evaluating different diagnostic and management strategies for acute non-complicated urinary conditions (for example, comparing short-course versus standard antibiotic regimens for uncomplicated pyelonephritis-like presentations, or algorithm-driven versus usual-care imaging pathways for suspected renal colic). These trials enroll adults admitted with kidney or urinary tract complaints that do not meet CC/MCC severity criteria, and focus on short-term clinical resolution, length of stay, and readmission. Results inform clinicians and payers about optimal inpatient resource utilization, antibiotic stewardship, and opportunities to reduce unnecessary testing while maintaining quality care.
    • Observational cohort and care-pathway implementation studies examining peri-hospitalization care coordination and early discharge programs for patients with stable urinary tract disorders (such as recurrent uncomplicated infections, obstructive symptoms without complications, or non-severe stone disease managed conservatively). These studies follow patients from admission through a defined post-discharge period to measure outcomes like 30-day readmission, emergency visits, patient-reported symptom control, and adherence to outpatient follow-up. Findings are relevant for designing bundled payment approaches and for providers/payers aiming to safely shorten hospital stays and reduce downstream costs while tracking quality metrics.
    • Interventional or registry-based studies focused on diagnostic accuracy and risk stratification tools for non-severe kidney and urinary tract diagnoses (for example, validation of clinical prediction rules, biomarkers, or point-of-care ultrasound protocols to differentiate patients who need inpatient interventions from those suitable for outpatient management). Patient populations include adults presenting with equivocal symptoms where the primary clinical question is disposition and need for invasive procedures. This research helps hospitals and payers by targeting high-value care, reducing unnecessary admissions and procedures, and informing guidelines that standardize admission criteria within this DRG.

    Related Codes

    650-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITH-MCC

    Kidney Transplant with Hemodialysis with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    651-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITHOUT-MCC

    Kidney Transplant with Hemodialysis without MCC: Inpatient Reimbursement Overview

    652-KIDNEY-TRANSPLANT

    Kidney Transplant: Inpatient Reimbursement Overview

    653-MAJOR-BLADDER-PROCEDURES-WITH-MCC

    Major Bladder Procedures with MCC: Inpatient Reimbursement Overview

    654-MAJOR-BLADDER-PROCEDURES-WITH-CC

    Major Bladder Procedures with CC: Inpatient Reimbursement Overview

    655-MAJOR-BLADDER-PROCEDURES-WITHOUT-CC-MCC

    Major Bladder Procedures without CC/MCC: Inpatient Reimbursement Overview

    656-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Neoplasm with MCC: Inpatient Reimbursement Overview

    657-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-CC

    Kidney and Ureter Procedures for Neoplasm with CC: Inpatient Reimbursement Overview

    658-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITHOUT-CC-MCC

    Kidney and Ureter Procedures for Neoplasm without CC/MCC: Inpatient Reimbursement Overview

    659-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Non-Neoplasm with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 41

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.